

IN THE CLAIMS:

Please cancel Claim 50, which is withdrawn from consideration, without prejudice.

Please amend the claims as follows:

51. (Amended) An isolated antibody which specifically binds to a eukaryotic elongation factor-2 kinase (eEF-2 kinase) capable of phosphorylating an amino acid within an alpha helical domain of eukaryotic elongation factor-2 (eEF-2), said kinase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:10.
52. (Amended) An isolated antibody which specifically binds to a human eEF-2 kinase capable of phosphorylating an amino acid within an alpha helical domain of eukaryotic elongation factor-2 (eEF-2), said kinase comprising the amino acid sequence of SEQ ID NO:2.
53. (Amended) A monoclonal antibody which specifically binds to a eukaryotic elongation factor-2 kinase (eEF-2 kinase) capable of phosphorylating an amino acid within an alpha helical domain of eukaryotic elongation factor-2 (eEF-2), said kinase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:10.
54. (Amended) An immortal cell line that produces a monoclonal antibody which specifically binds to a eukaryotic elongation factor-2 kinase (eEF-2 kinase) capable of phosphorylating an amino acid within an alpha helical domain of eukaryotic elongation factor-2 (eEF-2), said kinase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:10.
55. (Amended) An isolated antibody which specifically binds to a eukaryotic elongation factor-2 kinase (eEF-2 kinase) capable of phosphorylating an amino acid within an alpha helical

domain of eukaryotic elongation factor-2 (eEF-2), said kinase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:10, said antibody labeled with a detectable label.

56. The antibody of Claim 54 55 wherein the label is selected from enzymes, chemicals which fluoresce and radioactive elements.

57. (Amended) A radioactively labeled antibody which specifically binds to a eukaryotic elongation factor-2 kinase (eEF-2 kinase) capable of phosphorylating an amino acid within an alpha helical domain of eukaryotic elongation factor-2 (eEF-2), said kinase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:10.

58. (Amended) An active fragment of an isolated antibody which specifically binds to a eukaryotic elongation factor-2 kinase (eEF-2 kinase) capable of phosphorylating an amino acid within an alpha helical domain of eukaryotic elongation factor-2 (eEF-2), said kinase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:10, said active fragment selected from the group of Fab, Fab', F(ab')<sub>2</sub> and Fv fragments.

59. (Amended) A pharmaceutical composition comprising:

A. a therapeutically effective amount of an antibody ~~directed~~ which specifically binds to a eukaryotic elongation factor-2 kinase (eEF-2 kinase) capable of phosphorylating an amino acid within an alpha helical domain of eukaryotic elongation factor-2 (eEF-2), said kinase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:10, or an active fragment of said antibody; and,

B. a pharmaceutically acceptable carrier.